StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

Tango Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Tango Therapeutics's price to sales ratio was 80.5× on Nov 11, 2026, against 18.3× a year earlier. Over the last 5 years it ranged from 3.5× to 80.5×, with a median of 20.6×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202680.5×+65.6
2025Dec 31, 202514.9×+7.2
2024Dec 31, 20247.7×−19.2
2023Dec 29, 202326.9×+0.5
2022Dec 30, 202226.4×+2.8
2021Dec 31, 202123.7×–

More Tango Therapeutics figures

See a number that looks wrong?